This event has ended. Visit the official site or create your own event on Sched.
This year, Partners in Digital Health, publishers of Blockchain in Healthcare Today and Teleheath and Medicine Today, presented a full day of concurrent tracks featuring  the foremost  innovators and savants in blockchain technology, telehealth, AI, and other novel technologies convened  at the Convege2Xcelerate  (#ConV2X),  healthcare modernization event,  to address the most compelling issues, growth opportunities, and financial implications for the industry.

Sector leadership  converged to share and challenge the integration of emerging technologies to accelerate building a new framework for the future of patient care, and modernization of a new health system.

Register now to receive your  podcast edition  alert from BHTY and TMT.

BHTY registration:  https://blockchainhealthcaretoday.com/index.php/journal/user/register
TMT registration: https://telehealthandmedicinetoday.com/index.php/journal/user/register


BurstIQ  |  1800PR  |  Cadent Medical Communication  | HealthVerity  |  Izzy  |  Nonnatech

Media Partners:
Healthcare Informatics  |  Health Data Management  |  Pharmacy Podcast

and all our Friends...

See you in 2019...!
avatar for Uli Broedl

Uli Broedl

Boehringer Ingelheim, Canada
Medical Director and Vice President of Medical and Regulatory Affairs
Dr. Uli Broedl, MD, is Medical Director and Vice President of Medical and Regulatory Affairs at Boehringer Ingelheim Canada since January 2017. He is the medical representative of the company’s executive leadership team and oversees all aspects of clinical operations, clinical development, medical affairs, regulatory affairs, drug safety and clinical quality management. Dr. Broedl is passionate about fostering innovation
and new disruptive technologies that hold promise to improve patient care (e.g., blockchain technology in healthcare).

After having joined Boehringer Ingelheim in 2009 as global Deputy Therapeutic Area Head Metabolism, Dr. Broedl was responsible for building a Late Clinical Development team that drove the global registrations of various glucose-lowering medications in patients with type 2 diabetes mellitus.

Dr. Broedl is adjunct Professor of Medicine at the University of Munich, Germany, and holds a Doctorate of Medicine degree from the University of Munich. He completed a Postdoctoral Fellowship in Dr. Daniel J. Rader ́s lab, Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, and completed his
training in Internal Medicine, Endocrinology and Metabolism at the Medical Center of the University of Munich.